Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
For all the scientific advances in drug development, clinical trials remain one of the most inefficient and fragile components of the system. Patient recruitment is slow and costly, retention rates ar...
Artificial intelligence has rapidly moved from a buzzword to a core component of modern drug development. From target identification and molecule design to clinical trial optimization, AI pr...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Canada’s biopharma sector is entering a defining phase where scientific ambition is increasingly intersecting with economic reality. Breakthroughs in gene therapies, precision medicine, and AI driven ...
